TY - CHAP M1 - Book, Section TI - Systemic Sarcoidosis A1 - Moller, David R. A1 - Chen, Edward S. A2 - Grippi, Michael A. A2 - Elias, Jack A. A2 - Fishman, Jay A. A2 - Kotloff, Robert M. A2 - Pack, Allan I. A2 - Senior, Robert M. A2 - Siegel, Mark D. PY - 2015 T2 - Fishman's Pulmonary Diseases and Disorders, 5e AB - Sarcoidosis is a multisystem disorder characterized by noncaseating granulomatous inflammation at sites of disease.1 Although any organ can be involved, the disease most commonly affects the lungs and intrathoracic lymph nodes. A diagnosis of sarcoidosis is most securely established from compatible clinical and radiologic findings, confirmed by a biopsy showing noncaseating epithelioid granulomas in more than one organ and the exclusion of granulomatous disorders of known cause. Clinical, epidemiologic, and family studies support the hypothesis that sarcoidosis is triggered by exposure to microbial agents in individuals with a genetic susceptibility to the disease. The clinical course is highly variable, with a mortality rate of <1% to 5%. Corticosteroids remain the mainstay of treatment for patients with threatened organ failure or progressive disease. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/06 UR - accessmedicine.mhmedical.com/content.aspx?aid=1122360628 ER -